Sincalide ammonium Cholecystokinin octapeptide ammonium; CCK-8 ammonium; SQ19844 ammonium|cas:70706-98-8|西域试剂

Sincalide ammonium Cholecystokinin octapeptide ammonium; CCK-8 ammonium; SQ19844 ammonium,99.90%

产品编号：Bellancom-P0093A| CAS NO：70706-98-8| 分子式：C₄₉H₆₅N₁₁O₁₆S₃| 分子量：1160.30

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-P0093A	￥1100.00	杭州北京（现货）
Bellancom-P0093A	￥3000.00	杭州北京（现货）
Bellancom-P0093A	￥4800.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Sincalide ammonium Cholecystokinin octapeptide ammonium; CCK-8 ammonium; SQ19844 ammonium

产品介绍

Sincalide ammonium (Cholecystokinin octapeptide ammonium, CCK-8 ammonium) 是一种速效胆囊收缩素 (CCK) 的 氨基酸多肽激素类似物，在胆囊造影术中静脉使用。Sincalide ammonium 是 CCK 的一个主要生物活性片段，它保留了 CCK 的大部分生物活性。可通过注射促进胆囊收缩并帮助诊断胆囊和胰腺疾病。其增加胆汁的分泌，使胆囊收缩并使 Oddi的括约肌松弛，从而使胆汁排入十二指肠。

生物活性

Sincalide ammonium (Cholecystokinin octapeptide ammonium, CCK-8 ammonium) is a rapid-acting amino acid polypeptide hormone analogue of cholecystokinin (CCK) for intravenous use in postevacuation cholecystography. Sincalide ammonium is a major bioactive segment of CCK that retains most of the biological activities of CCK. CCK‐8 can promote gallbladder contraction by injection and helps diagnose gallbladder and pancreas disorders. Sincalide ammonium can increase bile secretion, cause the gallbladder to contract and relax the sphincter of Oddi, resulting in bile drainage into the duodenum. Sincalide ammonium is a major bioactive segment of CCK that retains most of the biological activities of CCK.

体外研究

Sincalide ammonium (Cholecystokinin octapeptide ammonium, CCK-8 ammonium), as a novel cardiovascular hormone, has a significant inhibitory effect on myocardial fibrosis in noninfarcted areas. Sincalide ammonium also plays a positive role in fighting inflammation, apoptosis and collagen deposition. CCK‐8 (ammonium) protects H9c2 cardiomyoblasts from Ang II‐induced apoptosis partly via activation of the CCK1 receptor and the phosphatidyqinositol‐3 kinase/protein kinase B (PI3K/Akt) signaling pathway.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assaysup>

Cell Line:	H9c2 cells
Concentration:	0.001, 0.01, 0.1, 1, 10, or 100 μmol/L
Incubation Time:	24 h
Result:	Attenuated Ang II‐induced toxicity in H9c2 cells

Apoptosis Analysis

Cell Line:	H9c2 cells
Concentration:	0.001, 0.01, 0.1, 1, 10, or 100 μmol/L
Incubation Time:	24 h
Result:	Decreased apoptotic cells, and prevented Ang II‐induced cytotoxicity that involves modulation of the PI3K/Akt pathway.

Western Blot Analysis

Cell Line:	H9c2 cells
Concentration:	0.001, 0.01, 0.1, 1, 10, or 100 μmol/L
Incubation Time:	24 h
Result:	Expressed the protein and mRNAs of CCK and both its receptors in H9c2 cells.

RT-PCR

Cell Line:	H9c2 cells
Concentration:	0.001, 0.01, 0.1, 1, 10, or 100 μmol/L
Incubation Time:	24 h
Result:	Increased the protein and mRNA expression levels of CCK and decreased CCK 1 receptor expression levels at both the protein and mRNA levels with Ang II stimulation markedly.

体内研究
(In Vivo)

Sincalide ammonium (Cholecystokinin octapeptide ammonium, CCK-8 ammonium) alleviates fibrosis in the noninfarcted regions and delay the left ventricular remodeling and the progress of heart failure in a MI rat model^[4].

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	MI rat model^[4]
Dosage:	50 μg/kg
Administration:	i.p.; 50 μg/kg/d; for 4 weeks
Result:	Had significant inhibitory effect on myocardial fibrosis in noninfarcted areas.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	MI rat model^[4]
Dosage:	50 μg/kg
Administration:	i.p.; 50 μg/kg/d; for 4 weeks
Result:	Had significant inhibitory effect on myocardial fibrosis in noninfarcted areas.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	MI rat model^[4]
Dosage:	50 μg/kg
Administration:	i.p.; 50 μg/kg/d; for 4 weeks
Result:	Had significant inhibitory effect on myocardial fibrosis in noninfarcted areas.

性状

Solid

溶解性数据

In Vitro:

H₂O : 12.5 mg/mL (10.77 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	0.8618 mL	4.3092 mL	8.6185 mL
5 mM	0.1724 mL	0.8618 mL	1.7237 mL
10 mM	0.0862 mL	0.4309 mL	0.8618 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Sealed storage, away from moisture and light, under nitrogen